• InMed Pharmaceuticals posted a net loss of USD 3 million for third-quarter fiscal 2026, widening from USD 2.1 million a year earlier.
• Research and development expenses more than doubled to USD 1 million, general and administrative costs edged up to USD 1.7 million.
• Cash, cash equivalents and short-term investments fell to USD 5.2 million as of March 31, 2026, from USD 10.8 million at June 30, 2025.
• BayMedica began winding down its commercial operations, the company’s only revenue-generating segment, with discontinued operations producing USD 0.7 million in revenue during the quarter.
• Management highlighted new preclinical data showing INM-901 reduced neuroinflammation in 3D human brain organoid models of Alzheimer’s disease, including dose-dependent declines in IL-6 and IL-8.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-26-002371), on May 07, 2026, and is solely responsible for the information contained therein.